Healthcare Industry News: Mylan
News Release - October 2, 2007
Mylan Announces Appointment of Didier Barret as President, Europe, Middle East and AfricaPITTSBURGH, Oct. 2 (HSMN NewsFeed) -- Mylan Inc. (NYSE: MYL ) today announced the appointment of Didier Barret to the position of President, EMEA (Europe, Middle East and Africa) following the completion of Mylan's acquisition of Merck's Generics Group today.
At Merck Generics, M. Barret most recently served as Region Director, EMEA, reporting to the CEO. He was promoted to that position in 2004 following his role as Area Director for Southern Europe, where he was responsible for France, Belgium, Italy, Spain and Portugal. He established Merck Generics' first operations in France in 1995, growing the business to exceed euro 341 million in sales by 2006. Prior to this, M. Barret held several positions within Merck's branded division, including sales and marketing in the UK and France.
Mylan Vice Chairman and CEO Robert J. Coury commented: "We are very pleased to welcome Didier to the senior leadership team at Mylan. He is a phenomenal operator and leader, having created Merck Generic's business in France literally from nothing to becoming the strong and growing business it is today. Under his leadership of the EMEA region since 2004, growth from operations in these territories has been extremely impressive, at around 12% annual compound growth. As we take our place as a global leader in the generics and specialty pharmaceutical industry, Didier will play a key role in ensuring that we maximize our many opportunities for growth and success moving forward in the EMEA region."
M. Barret said: "I am very excited to be part of the new Mylan. There is a real cultural fit between our organizations and the new management team under Robert is very much operating with a unified vision. Together, our combined company is truly a world leader in our industry, with the depth and scale in terms of product portfolio and pipeline, as well as manufacturing and R&D, to provide our customers, and ultimately patients, with the best quality products and service available. I look forward to being a part of Mylan's future success. I also want to take the opportunity to thank my teams in EMEA for their hard work and the contributions each has made to the success of our business to date and for their commitment to making the new Mylan even more successful in the future."
Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey L.P., Mylan's fully integrated specialty business, provides the Company with innovative and Diversified opportunities in the respiratory and allergy therapeutic areas.
With manufacturing, packaging, distribution and marketing capabilities, Mylan EMEA holds leading positions in several fast-growing markets throughout Europe including France, Germany, United Kingdom, Italy, Spain, Austria, Greece, Ireland, Belgium, Netherlands, Portugal, Scandinavia, as well as South Africa and Morocco.
For more information about Mylan, please visit www.Mylan.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsMylan Launches Generic Suboxone(R) Sublingual Film to Treat Opioid Dependence
Sanofi's Formulation Patents on Multibillion-Dollar Lantus(R) are Invalidated by U.S. Patent and Trademark Office via IPR, Announces Mylan
Mylan Expands Gastroenterology Portfolio with Launch of Generic for Prevacid(R) SoluTab Delayed-Release Orally Disintegrating Tablets